347: More HHS upheaval, 23andMe's bankruptcy, and AI for cancer survival
The Readout Loud
Breakthrough in Prader-Willi Treatment
This chapter explores the approval of Vicat XR, the first dedicated drug for Prader-Willi syndrome, discussing its implications for patients and the challenges overcome during its development. It also examines the broader context of rare genetic diseases and the evolving landscape of genetics in biotechnology.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
